This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 May;11(5):988-9.

doi: 10.1111/jth.12167.

Recommendations on the potency labelling of factor VIII and factor IX concentrates

A R Hubbard¹, J Dodt, T Lee, K Mertens, R Seitz, A Srivastava, M Weinstein; Factor VI I I and Factor IX Subcommittee of The Scientific and Standardisation Committee of The International Society on Thrombosis and Haemostasis

Affiliations

PMID: 23406084
DOI: 10.1111/jth.12167

Free article

Recommendations on the potency labelling of factor VIII and factor IX concentrates

A R Hubbard et al. J Thromb Haemost. 2013 May.

Free article

. 2013 May;11(5):988-9.

doi: 10.1111/jth.12167.

Authors

A R Hubbard¹, J Dodt, T Lee, K Mertens, R Seitz, A Srivastava, M Weinstein; Factor VI I I and Factor IX Subcommittee of The Scientific and Standardisation Committee of The International Society on Thrombosis and Haemostasis

Affiliation

¹ National Institute for Biological Standards and Control, Potters Bar, UK. anthony.hubbard@nibsc.hpa.org.uk

PMID: 23406084
DOI: 10.1111/jth.12167

No abstract available

PubMed Disclaimer

Similar articles

The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
Morfini M, Lee M, Messori A. Morfini M, et al. Thromb Haemost. 1991 Sep 2;66(3):384-6. Thromb Haemost. 1991. PMID: 1746011 No abstract available.
New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D, Peerlinck K, Jacquemin M. Van den Bossche D, et al. Int J Lab Hematol. 2018 May;40 Suppl 1:21-29. doi: 10.1111/ijlh.12813. Int J Lab Hematol. 2018. PMID: 29741261 Review.
Pharmacokinetics of factor VIII and factor IX.
Morfini M. Morfini M. Haemophilia. 2003 May;9 Suppl 1:94-9; discussion 100. doi: 10.1046/j.1365-2516.9.s1.8.x. Haemophilia. 2003. PMID: 12709044 Review.
Comparative pharmacokinetic studies in haemophilia.
Morfini M. Morfini M. Haemophilia. 2002 Mar;8 Suppl 2:30-3. doi: 10.1046/j.1351-8216.2002.00136.x. Haemophilia. 2002. PMID: 11966850 Review.
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ, Obaji SG, Collins PW. Mahdi AJ, et al. Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7. Br J Haematol. 2015. PMID: 25754016 Review.

See all similar articles

Cited by

Estimation of Nuwiq^® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.
Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories. Tiefenbacher S, et al. Haemophilia. 2019 Jul;25(4):708-717. doi: 10.1111/hae.13763. Epub 2019 May 20. Haemophilia. 2019. PMID: 31106957 Free PMC article.
Performance of factor IX extended half-life product measurements in external quality control assessment programs.
Nederlof A, Kitchen S, Meijer P, Cnossen M, Ali Pour N, Kershaw G, Jennings I, Walker I, de Maat MPM. Nederlof A, et al. J Thromb Haemost. 2020 Aug;18(8):1874-1883. doi: 10.1111/jth.14847. Epub 2020 Jun 10. J Thromb Haemost. 2020. PMID: 32311825 Free PMC article.
Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C, Négrier C, Kalina U, Seifert W, Friedman KD. Horn C, et al. J Thromb Haemost. 2019 Jan;17(1):138-148. doi: 10.1111/jth.14332. Epub 2018 Dec 16. J Thromb Haemost. 2019. PMID: 30418692 Free PMC article.
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E. Chowdary P, et al. Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul. Res Pract Thromb Haemost. 2019. PMID: 31294338 Free PMC article.
A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
Tiefenbacher S, Clausen WHO, Hansen M, Lützhøft R, Ezban M. Tiefenbacher S, et al. Haemophilia. 2019 Sep;25(5):893-901. doi: 10.1111/hae.13813. Epub 2019 Jul 11. Haemophilia. 2019. PMID: 31294905 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations